Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Unique Kinase Found Important for Parasite Survival and Virulence

By BiotechDaily International staff writers
Posted on 01 Jan 2014
Image: Phase contrast showing location of whole cells (Photo courtesy of Prof. C.L. Jaffe, Hebrew University, and of PLOS One).
Image: Phase contrast showing location of whole cells (Photo courtesy of Prof. C.L. Jaffe, Hebrew University, and of PLOS One).
Image: Presence of Casein Kinase 1 isoform 4 (CK1.4) in Leishmania donovani shown by immunoflourescent staining (red); control staining of nuclei is shown in blue (Photo courtesy of Prof. C.L. Jaffe, Hebrew University, and of PLOS One).
Image: Presence of Casein Kinase 1 isoform 4 (CK1.4) in Leishmania donovani shown by immunoflourescent staining (red); control staining of nuclei is shown in blue (Photo courtesy of Prof. C.L. Jaffe, Hebrew University, and of PLOS One).
A unique protein kinase (PK) secreted by the human parasite Leishmania was found to be important for the parasite's growth and virulence, making it a potential new chemotherapeutic target against leishmaniasis.

Enzymes of the casein kinase 1 (CK1) family are present in all known eukaryotes and are involved in a wide variety of cellular processes. Scientists at the Hebrew University - Hadassah Medical School (Jerusalem, Israel) led by Charles Jaffe, professor at the Department of Microbiology and Molecular Genetics, and Kuvin Center for the Study of Infectious and Tropical Diseases, investigated the role of CK1 isoform 4, unique to Leishmania (LCK1.4) and one of six putative CK1 isoforms encoded in the leishmanial genome.

In the study published in the journal PLOS One on November 15, 2013, Dan-Goor et al. investigated LCK1.4 in Leishmania donovani (LdCK1.4), a species that causes fatal, visceral disease. Full-length recombinant protein and three deletion constructs were cloned and expressed in E. coli. Only the full-length PK demonstrated significant activity, suggesting that both the N- and C-regions are required for LdCK1.4 PK activity.

Analysis of the LdCK1.4 amino acid sequence identified a putative secretion signal. To determine whether this PK is secreted, a C-terminus FLAG-tagged form, LdCK1.4-FLAG, was constructed and stably overexpressed in L. donovani promastigote-stage cells. LdCK1.4-FLAG or wild-type LdCK1.4 (native, untagged) release by mutant and/or wild-type parasites was monitored by Western blotting with polyclonal anti-LdCK1.4 and anti-FLAG upon transfer to induction buffer. The released PK was clearly observed in cell-free supernatants, peaking at 10 minutes. Differences in kinetics of release, and amounts of enzyme, were observed between mutant and wild type parasites.

LdCK1.4 was localized in fixed dividing-stage promastigotes using antibodies. Intracellular fluorescence was present both as weak diffuse cytoplasmic staining, as well as a strong punctate pattern adjacent to the nucleus and/or kinetoplast (no co-localization with a nuclear staining control was observed). This suggests that CK1.4 may have intracellular, as well as secreted extracellular roles.

Effect of LdCK1.4-FLAG overexpression on parasite growth and differentiation into virulent, metacyclic-stage promastigotes was examined daily. Parasites overexpressing the PK grew significantly faster, noted by day 3, and to higher densities than control cells. Interestingly, the LdCK1.4-FLAG overexpressing mutants differentiated more rapidly in culture, on day 3, into the metacyclic, virulent stage, than the wild-type parasites, as measured by flow cytometry. However, the final percentage of metacyclic parasites in stationary growth-phase cultures, on day 5, was similar in both types of parasites.

The researchers also examined the effect of LdCK1.4 overexpression on parasite virulence. CK1.4 expression increases rapidly during differentiation from the insect promastigote stage to intracellular amastigote stage in the mammalian host. Day 5 stationary phase promastigotes were used to infect mouse macrophages and intracellular amastigote infection was measured 72 hours later. The percentage of infected macrophages was significantly higher (~4.5–fold, p<0.0005) with the mutant, LdCK1.4-FLAG overexpressing parasites (~28%) compared to the wild-type parasites (~6%). Only a small, but significant difference in the number of parasites per infected macrophage was observed. Further characterization of LCK1.4 and its role in parasite survival and virulence will establish the potential of this unique leishmanial protein kinase as a putative drug target.

Related Links:

Hebrew University - Hadassah Medical School



SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
RANDOX LABORATORIES
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.